Sight Sciences (NASDAQ:SGHT) EVP Brenton Taylor Sells 14,418 Shares

Sight Sciences, Inc. (NASDAQ:SGHT) EVP Brenton Taylor sold 14,418 shares of the stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $7.06, for a total value of $101,791.08. Following the transaction, the executive vice president owned 170,831 shares in the company, valued at $1,206,066.86. This trade represents a 7.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Brenton Taylor also recently made the following trade(s):

• On Monday, October 6th, Brenton Taylor sold 591 shares of Sight Sciences stock. The stock was sold at an average price of $3.37, for a total value of $1,991.67.

Sight Sciences Price Performance

SGHT traded up $0.11 during midday trading on Tuesday, hitting $7.14. The stock had a trading volume of 128,269 shares, compared to its average volume of 193,256. Sight Sciences, Inc. has a 1 year low of $2.03 and a 1 year high of $8.06. The company has a debt-to-equity ratio of 0.62, a quick ratio of 8.93 and a current ratio of 9.60. The business has a fifty day moving average of $4.42 and a 200 day moving average of $3.99. The company has a market cap of $377.49 million, a P/E ratio of -7.93 and a beta of 2.46.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings data on Wednesday, September 8th. The company reported ($0.81) earnings per share for the quarter. Sight Sciences had a negative return on equity of 61.59% and a negative net margin of 60.63%.The business had revenue of $12.54 million during the quarter. As a group, equities analysts forecast that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SGHT has been the subject of several analyst reports. Morgan Stanley upped their price target on shares of Sight Sciences from $4.00 to $6.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th. Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a research note on Thursday, August 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Sight Sciences in a report on Wednesday, October 8th. Citigroup decreased their price target on Sight Sciences from $4.50 to $4.00 and set a “neutral” rating on the stock in a research note on Tuesday, October 7th. Finally, Piper Sandler boosted their price objective on Sight Sciences from $4.00 to $5.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Three analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $5.17.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SGHT. KCK LTD. bought a new stake in shares of Sight Sciences during the 2nd quarter valued at about $18,069,000. Acadian Asset Management LLC raised its stake in Sight Sciences by 127.7% in the first quarter. Acadian Asset Management LLC now owns 432,541 shares of the company’s stock worth $1,033,000 after buying an additional 242,559 shares in the last quarter. Palumbo Wealth Management LLC bought a new position in Sight Sciences in the second quarter worth about $328,000. Long Focus Capital Management LLC lifted its holdings in Sight Sciences by 39.7% in the first quarter. Long Focus Capital Management LLC now owns 3,126,508 shares of the company’s stock worth $7,504,000 after buying an additional 887,876 shares during the period. Finally, Americana Partners LLC bought a new stake in Sight Sciences during the 2nd quarter valued at approximately $3,568,000. 55.51% of the stock is currently owned by institutional investors.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.